Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates

Telles, María Alice da Silva; Chimara, Érica; Ferrazoli, Lucilaine; Riley, Lee W.

doi:10.1099/jmm.0.45965-0

Cited by 45 publications

(42 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since the CLSI has not yet addressed the breakpoints of clofazimine, dapsone and d-cycloserine for RGM [9], the susceptibility categories of these drugs for RGM cannot be assigned. By referring to the breakpoints used to define resistance to clofazimine and d-cycloserine for M. kansasii and M. tuberculosis [3,6] (no breakpoints for dapsone are available for mycobacteria), we tentatively grouped the MICs into …”

Section: Choosing An Appropriate Solvent For Clofazimine and Dapsonementioning

confidence: 99%

“…In addition, we found that the cyclic peptide capreomycin, which has been used to treat multidrug-resistant tuberculosis (MDR-TB), was effective against M. fortuitum but showed poor activity against M. abscessus and M. chelonae [1]. Other studies have indicated that clofazimine, dapsone and d-cycloserine are effective against MDR-TB, Mycobacterium kansasii, Mycobacterium avium complex (MAC) and Mycobacterium leprae [3][4][5][6]. In this study, we examined the in vitro effects of clofazimine, dapsone and d-cycloserine against RGM isolates.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria

Shen

Hu³

et al. 2010

International Journal of Antimicrobial Agents

110

View full text Add to dashboard Cite

Section: Choosing An Appropriate Solvent For Clofazimine and Dapsonementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria

Shen

Hu³

et al. 2010

International Journal of Antimicrobial Agents

110

View full text Add to dashboard Cite

“…ycobacterium kansasii is the third most common mycobacterial cause of chronic disease in the United States but the second most common after tuberculosis in other parts of the world (1)(2)(3)(4)(5). Although it has been associated with AIDS, worldwide there are many more cases of non-AIDS patients (1,6).…”

mentioning

confidence: 99%

Rapid Drug Tolerance and Dramatic Sterilizing Effect of Moxifloxacin Monotherapy in a Novel Hollow-Fiber Model of Intracellular Mycobacterium kansasii Disease

Srivastava

Pasipanodya

Sherman

et al. 2015

Antimicrob Agents Chemother

View full text Add to dashboard Cite

e Mycobacterium kansasii is the second most common mycobacterial cause of lung disease. Standard treatment consists of rifampin, isoniazid, and ethambutol for at least 12 months after negative sputum. Thus, shorter-duration therapies are needed. Moxifloxacin has good MICs for M. kansasii. However, good preclinical models to identify optimal doses currently are lacking. We developed a novel hollow fiber system model of intracellular M. kansasii infection. We indexed the efficacy of the standard combination regimen, which was a kill rate of ؊0.08 ؎ 0.05 log 10 CFU/ml/day (r 2 ‫؍‬ 0.99). We next performed moxifloxacin doseeffect and dose-scheduling studies at a half-life of 11.1 ؎ 6.47 h. Some systems also were treated with the efflux pump inhibitor reserpine. The highest moxifloxacin exposure, as well as lower exposures plus reserpine, sterilized the cultures by day 7. This suggests that efflux pump-mediated tolerance at low ratios of the area under the concentration-time curve from 0 to 24 h (AUC 0-24 ) to MICs is an early bacterial defense mechanism but is overcome by higher exposures. The highest rate of moxifloxacin monotherapy sterilization was ؊0.82 ؎ 0.15 log 10 CFU/ml/day (r 2 ‫؍‬ 0.97). The moxifloxacin exposure associated with 80% of maximal kill (EC 80 ) was an AUC 0 -24 /MIC of 317 (the non-protein-bound moxifloxacin AUC 0 -24 /MIC was 158.5). We performed Monte Carlo simulations of 10,000 patients in order to identify the moxifloxacin dose that would achieve or exceed the EC 80 . The simulations revealed an optimal moxifloxacin dose of 800 mg a day. The MIC susceptibility breakpoint at this dose was 0.25 mg/liter. Thus, moxifloxacin, at high enough doses, is suitable to study in patients for the potential to add rapid sterilization to the standard regimen. Mycobacterium kansasii is the third most common mycobacterial cause of chronic disease in the United States but the second most common after tuberculosis in other parts of the world (1-5). Although it has been associated with AIDS, worldwide there are many more cases of non-AIDS patients (1, 6). Data on treatments tested in randomized controlled clinical trials are scant. The recommended treatment in non-HIV-infected patients consists of isoniazid, rifampin, and ethambutol; this regimen was copied from that used to treat tuberculosis (4). It is recommended that patients receive therapy for more than 12 months after negative sputum, making the therapy duration even longer than that for tuberculosis (7). Therefore, it is important to identify a shorter-duration therapy. The quinolone moxifloxacin has been shown to have very good MICs in M. kansasii clinical isolates, with 90% of isolates having a MIC of Յ0.06 mg/liter (8). However, given the M. kansasii disease patient population sizes and social distribution and the lack of advocacy for this disease, it is unlikely that true randomized controlled clinical trials will be performed with this drug in the foreseeable future. One approach is to develop a good preclinical disease model whose results can be...

show abstract

“…Symptomatology includes edema, sensitivity and erythema (7) . In the therapeutic context, the initial treatment of any infection after breast implants is empirical antibiotic therapy and if symptoms and periprosthetic infection do not (23 ) To characterize the profiles of susceptibility of clinical isolates of M. kansasii through the CIM method To analyze the m ain facto rs for infections caused by M. massiliense related to the clone BRA100 resistant to GA 2%.…”

Section: Discussionmentioning

confidence: 99%

“…In this context, empirical antibiotic therapy should be implemented for at least six months and include, whenever possible, a surgical approach to remove infected tissue or any other foreign body to ensure the success of therapy (4,8) . Given the previous discussion, the identification of species is important for implementing appropriate therapy, because isolated strains of clinical cases present differences in patterns of sensitivity to antimicrobial agents (1,23) . We also highlight the possibility of harmonic association among different microorganisms.…”

Section: Nonrandomized Experimentsmentioning

confidence: 99%

Micobactérias não tuberculosas em cirurgias: desafio passível de enfrentamento no Brasil?

Cabral¹,

Andrade

2011

Acta paul. enferm.

View full text Add to dashboard Cite

Infections caused by nontuberculous mycobacteria (MNT) represent an epidemiological and health emergency, especially in patients undergoing invasive procedures. Based on these, we aimed to analyze the scientific evidence, the scientific literature, on the occurrence in Brazil of MNT infections in surgical patients. We used as a research method integrative review of the literature using the databases Lilacs, Medline/Pubmed, ISI Web of Science and the Cochrane Library. We selected 15 publications on this theme from the last 30 years that were directed at methods of prevention and control, with a focus on post-discharge surveillance, the use of antibiotics and glutaraldehyde. Eye surgery, cosmetic, heart, laparoscopic and arthroscopic procedures were the most commonly investigated. The national situation of MNTs is concerning, especially when one recognizes the possibility of underreporting. Keywords: Mycobacteria, atypical; Surgical procedures operative; Mycobacterium infections atypical RESUMOInfecções por micobactéria não tuberculosa (MNT) representam uma emergência epidemiológica e sanitária, especialmente, em pacientes submetidos a procedimentos invasivos. Frente ao exposto, objetivou-se analisar as evidências científicas, na literatura científica, sobre a ocorrência no Brasil de infecções por MNT em pacientes cirúrgicos. Utilizou-se como método de pesquisa a revisão integrativa da literatura nas bases de dados Lilacs, Medline/Pubmed, ISI Web of Science e Biblioteca Cochrane. Foram selecionadas 15 publicações sobre a temática nos últimos 30 anos que estavam direcionadas às medidas de prevenção e controle com foco na vigilância pós-alta, no uso de antibioticoterapia e glutaraldeído. Cirurgias oftalmológicas, estéticas, cardíacas e procedimentos laparoscópicos e artroscópicos foram as mais investigadas. A situação nacional das MNTs é preocupante, ainda mais quando se reconhece a possibilidade de subnotificação. Descritores: Micobactérias atípicas; Procedimentos cirúrgicos operatórios; Infecções atípicas por Mycobacterium RESUMENLas infecciones por micobacteria no tuberculosa (MNT) representan una emergencia epidemiológica y sanitaria, especialmente, en pacientes sometidos a procedimientos invasivos. Frente a lo expuesto, se tuvo como objetivo analizar las evidencias científicas, en la literatura científica, sobre la ocurrencia en el Brasil de infecciones por MNT en pacientes quirúrgicos. Se utilizó como método de investigación la revisión integrativa de la literatura en las bases de datos Lilacs, Medline/Pubmed, ISI Web of Science y Biblioteca Cochrane. Se seleccionaron 15 publicaciones sobre la temática en los últimos 30 años que estaban orientadas a las medidas de prevención y control con foco en la vigilancia post alta, en el uso de antibioticoterapia y glutaraldehido. Cirugías oftalmológicas, estéticas, cardíacas y procedimientos laparoscópicos y artroscópicos fueron las más investigadas. La situación nacional de las MNTs es preocupante, aun más cuando se reconoce la posibilidad de subnotificación.

show abstract

Mycobacterium kansasii: antibiotic susceptibility and PCR-restriction analysis of clinical isolates

Cited by 45 publications

References 26 publications

High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria

High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria

Rapid Drug Tolerance and Dramatic Sterilizing Effect of Moxifloxacin Monotherapy in a Novel Hollow-Fiber Model of Intracellular Mycobacterium kansasii Disease

Micobactérias não tuberculosas em cirurgias: desafio passível de enfrentamento no Brasil?

Contact Info

Product

Resources

About